Suppr超能文献

糖尿病患者心血管疾病的一级预防

Primary Prevention of Cardiovascular Disease in Diabetes Mellitus.

作者信息

Newman Jonathan D, Schwartzbard Arthur Z, Weintraub Howard S, Goldberg Ira J, Berger Jeffrey S

机构信息

Division of Cardiology and the Center for the Prevention of Cardiovascular Disease, Department of Medicine, New York University Medical Center; New York, New York.

Division of Cardiology and the Center for the Prevention of Cardiovascular Disease, Department of Medicine, New York University Medical Center; New York, New York.

出版信息

J Am Coll Cardiol. 2017 Aug 15;70(7):883-893. doi: 10.1016/j.jacc.2017.07.001.

Abstract

Type 2 diabetes mellitus (T2D) is a major risk factor for cardiovascular disease (CVD), the most common cause of death in T2D. Yet, <50% of U.S. adults with T2D meet recommended guidelines for CVD prevention. The burden of T2D is increasing: by 2050, approximately 1 in 3 U.S. individuals may have T2D, and patients with T2D will comprise an increasingly large proportion of the CVD population. The authors believe it is imperative that we expand the use of therapies proven to reduce CVD risk in patients with T2D. The authors summarize evidence and guidelines for lifestyle (exercise, nutrition, and weight management) and CVD risk factor (blood pressure, cholesterol and blood lipids, glycemic control, and the use of aspirin) management for the prevention of CVD among patients with T2D. The authors believe appropriate lifestyle and CVD risk factor management has the potential to significantly reduce the burden of CVD among patients with T2D.

摘要

2型糖尿病(T2D)是心血管疾病(CVD)的主要危险因素,而心血管疾病是T2D最常见的死亡原因。然而,在美国患有T2D的成年人中,只有不到50%符合推荐的CVD预防指南。T2D的负担正在增加:到2050年,大约三分之一的美国人可能患有T2D,并且T2D患者在CVD人群中所占比例将越来越大。作者认为,我们必须扩大使用已被证明可降低T2D患者CVD风险的治疗方法。作者总结了生活方式(运动、营养和体重管理)以及CVD危险因素(血压、胆固醇和血脂、血糖控制以及阿司匹林的使用)管理的证据和指南,以预防T2D患者的CVD。作者认为,适当的生活方式和CVD危险因素管理有可能显著减轻T2D患者的CVD负担。

相似文献

1
Primary Prevention of Cardiovascular Disease in Diabetes Mellitus.糖尿病患者心血管疾病的一级预防
J Am Coll Cardiol. 2017 Aug 15;70(7):883-893. doi: 10.1016/j.jacc.2017.07.001.
2
Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes.改善 2 型糖尿病患者的心血管风险。
Endocrinol Metab Clin North Am. 2023 Mar;52(1):135-147. doi: 10.1016/j.ecl.2022.07.002. Epub 2022 Nov 18.

引用本文的文献

2
Peripheral artery disease In West Africans with diabetes: a risk factor profile analysis.西非糖尿病患者的外周动脉疾病:危险因素剖析
Int J Cardiol Cardiovasc Risk Prev. 2025 Jul 11;26:200469. doi: 10.1016/j.ijcrp.2025.200469. eCollection 2025 Sep.
10
Aging and Cardiovascular Disease: Current Status and Challenges.衰老与心血管疾病:现状与挑战
Rev Cardiovasc Med. 2022 Apr 8;23(4):135. doi: 10.31083/j.rcm2304135. eCollection 2022 Apr.

本文引用的文献

2
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
3
Interpretation of the evidence for the efficacy and safety of statin therapy.他汀类药物治疗疗效和安全性证据解读。
Lancet. 2016 Nov 19;388(10059):2532-2561. doi: 10.1016/S0140-6736(16)31357-5. Epub 2016 Sep 8.
5
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验